Drugs / FTL008.16
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06410131 | May 2025 → Nov 2026 expected | cancer | Sound Biopharmaceuticals Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-25 | Sound Biopharmaceuticals Ltd. | Regulatory 非同生物首款双抗产品获批美国IND soundbiopharma.com ↗
美国东部时间2024年2月2日，非同（成都）生物科技有限公司自主研发的双特异性抗体药物FTL008.16的临床试验申请（IND）获得美国食品药品监督管理局（FDA）批准。 |
| 2026-08-25 | Sound Biopharmaceuticals Ltd. | Results 非同生物FTL008.16双抗项目最新研究成果登上《OncoImmunology》 soundbiopharma.com ↗
体外结果显示，FTL008.16 结合 4-1BB 的表位与天然配体重叠，可激活 TRAF2/NF-κB 通路；其激活强度与细胞 5T4 表达量正相关，仅杀伤 5T4 阳性肿瘤，不会诱导PBMC 释放炎症因子，并优先扩增细胞毒性CD8⁺T 细胞。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-25 | Sound Biopharmaceuticals Ltd. | 非同生物首款双抗产品获批美国IND soundbiopharma.com ↗ |
| 2026-08-25 | Sound Biopharmaceuticals Ltd. | 非同生物FTL008.16双抗项目最新研究成果登上《OncoImmunology》 soundbiopharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FTL008.16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06410131 ↗ |
| Modality | Monoclonal antibody | “a Recombinant Anti-CD137 and Anti-5T4 Bispecific Antibody” NCT06410131 ↗ |
| Route | Intravenous | “IV infusion every 2 weeks” NCT06410131 ↗ |